Effect of Saroglitazar on Glycemic Status: A Meta-analysis

Figures

• 

  Figure 1. PRISMA flow diagram of the study selection process PRISMA: Preferred Reporting Items for Systematic reviews and Meta-Analysis

• 

  Figure 2. Effect of saroglitazar on HbA1C levels Figure 2a: Overall (observational studies and RCTs) [5,11-15,17-22] Figure 2b: Observational studies [11-15] Figure 2c: RCTs comparing saroglitazar vs. placebo [5,17-22] Figure 2d: Saroglitazar 2 mg vs. 4 mg [5,18,19] HbA1c: Glycated hemoglobin; RCT: Randomized controlled trial.

• 

  Figure 3. Effect of saroglitazar on FBS and PPBS levels Figure 3a: Effect of saroglitazar on FBS (overall) [5,11,15,17-21] Figure 3b: Effect of saroglitazar on FBS (randomized controlled trials) [5,17-21] Figure 3c: Effect of saroglitazar on FBS (observational) [11,15] Figure 3d: Effect of saroglitazar on PPBS (overall) [5,11,15,17] FBS: Fasting blood sugar; PPBS: Post-prandial blood sugar.

• 

  Figure 4. Forest plot showing reduction in the lipid levels with saroglitazar 2 mg or 4 mg for the treatment of diabetic dyslipidemia (randomized controlled trials) Figure 4a: Total cholesterol [5,17-22] Figure 4b: Triglycerides [5,17-22] Figure 4c: LDL [5,17-22] Figure 4d: VLDL [5,18,19] Figure 4e: HDL [5,17-22] HDL: High-density lipoprotein; LDL: Low-density lipoprotein; VLDL: Very-low-density lipoprotein.

• 

  Figure 5. Forest plot showing reduction in lipid levels with saroglitazar 4 mg for the treatment of diabetic dyslipidemia (observational studies) Figure 5a: Total cholesterol [11-15] Figure 5b: Triglycerides [11-15] Figure 5c: LDL [11-15] Figure 5d: VLDL [13,15] Figure 5e: HDL [11,13-15] HDL: High-density lipoprotein; LDL: Low-density lipoprotein; VLDL: Very-low-density lipoprotein.